ArticleVeterinarni medicina2026
Impact of histological and molecular subtype on the potential therapeutic effect of buparlisib in canine mammary gland tumours.
Article in Veterinarni medicina, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the response of primary cells to buparlisib, a PI3K inhibitor, at varying concentrations and exposure durations across different histological and molecular subtypes of CMGTs, and to assess PI3K/Akt/mTOR pathway activity by measuring Akt and mTOR expression. Three carcinomas (C), three sarcomas (S), and two carcinosarcomas (CS) tumours were collected from the dogs. The primary cells were produced from tissues and treated with buparlisib at different doses. Subsequently, the WST-1 assay, Annexin V, and AO/PI staining were performed sequentially to evaluate the effects of buparlisib. PI3K/Akt/mTOR signalling pathway inhibition was revealed at the gene level in C, S, and CS cells following 5 µM buparlisib treatment by RT-PCR analysis. Our results demonstrated that C1 and C2 (basal-like) cells were more sensitive than C3, CS1, and CS2 cells (luminal A) upon buparlisib treatment. Liposarcoma S2 cells responded more to buparlisib than undifferentiated S cells (S1 and S3). Buparlisib also induced apoptosis and inhibited
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.